135 related articles for article (PubMed ID: 10764169)
1. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML).
Green CL; Loken M; Buck D; Deeg HJ
Leukemia; 2000 Apr; 14(4):770-2. PubMed ID: 10764169
[No Abstract] [Full Text] [Related]
2. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
3. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
Xie W; Wang X; Du W; Liu W; Qin X; Huang S
Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
[TBL] [Abstract][Full Text] [Related]
4. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.
Florian S; Sonneck K; Hauswirth AW; Krauth MT; Schernthaner GH; Sperr WR; Valent P
Leuk Lymphoma; 2006 Feb; 47(2):207-22. PubMed ID: 16321850
[TBL] [Abstract][Full Text] [Related]
5. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein.
Guenova M; Balatzenko G
Hematology; 2008 Jun; 13(3):137-41. PubMed ID: 18702870
[TBL] [Abstract][Full Text] [Related]
6. AC133 antigen as a prognostic factor in acute leukemia.
Lee ST; Jang JH; Min YH; Hahn JS; Ko YW
Leuk Res; 2001 Sep; 25(9):757-67. PubMed ID: 11489469
[TBL] [Abstract][Full Text] [Related]
7. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors.
Bühring HJ; Seiffert M; Marxer A; Weiss B; Faul C; Kanz L; Brugger W
Blood; 1999 Jul; 94(2):832-3. PubMed ID: 10438201
[No Abstract] [Full Text] [Related]
8. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
[TBL] [Abstract][Full Text] [Related]
9. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
10. CD123 monoclonal antibody in myelodysplastic syndrome.
De Salvo L; Salas R; De Salvo D; Medina WJ; Nunez A; Plumacher Z; Fernandez O; Acosta M; Duerto M; Paz L; Salas D; Fuenmayor A
Hematol Oncol Stem Cell Ther; 2011; 4(2):107. PubMed ID: 21727775
[No Abstract] [Full Text] [Related]
11. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.
Arber DA; Slovak ML; Popplewell L; Bedell V; Ikle D; Rowley JD;
Am J Clin Pathol; 2002 Feb; 117(2):306-13. PubMed ID: 11863228
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia.
Maynadié M; Gerland L; Aho S; Girodon F; Bernier M; Brunet C; Campos L; Daliphard S; Deneys V; Falkenrodt A; Jacob MC; Kühlein E; LeCalvez G; Moskovtchenko P; Philip P; Carli PM; Faure GC; Béné MC;
Haematologica; 2002 Aug; 87(8):795-803. PubMed ID: 12161354
[TBL] [Abstract][Full Text] [Related]
15. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome].
Wang W; Wang HY; Zhao HX; Cui ZG; Li GL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):470-3. PubMed ID: 17605847
[TBL] [Abstract][Full Text] [Related]
18. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D
Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751
[TBL] [Abstract][Full Text] [Related]
19. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig WD
Haematologica; 2001 Feb; 86(2):154-61. PubMed ID: 11224484
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia and related conditions.
Todd WM
Hematol Oncol Clin North Am; 2002 Apr; 16(2):301-19. PubMed ID: 12094474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
